Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI
Status:
Recruiting
Trial end date:
2022-03-20
Target enrollment:
Participant gender:
Summary
In summary, this small-scale study is designed to demonstrate that the NFX88 is safe and well
tolerated, as well as preliminary evidence of improvement in the score of VAS, PD-Q, and PGIC
scales.